Moreover, patients with TRIB3H tumors had lower rates of overall survival (TCGA-BRCA; Supplementary Fig. 1b) and metastasis-free survival (PubMed GEO Datasets; Supplementary Fig. 1c) among ER+, HER2+, and triple-negative breast cancer patients. Here, ERBB2 is linked to triple-negative breast carcinoma.